Rankings
▼
Calendar
CRDF FY 2023 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena
CRDF
Cardiff Oncology, Inc.
$139M
FY 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$488,000
+26.4% YoY
Gross Profit
$488,000
100.0% margin
Operating Income
-$45M
-9305.7% margin
Net Income
-$41M
-8492.0% margin
EPS (Diluted)
$-0.93
Cash Flow
Operating Cash Flow
-$31M
Free Cash Flow
-$31M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$82M
Total Liabilities
$12M
Stockholders' Equity
$70M
Cash & Equivalents
$22M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$488,000
$386,000
+26.4%
Gross Profit
$488,000
$386,000
+26.4%
Operating Income
-$45M
-$40M
-13.8%
Net Income
-$41M
-$39M
-7.1%
← Q4 2022
All Quarters
Q1 2023 →